NCT00666237

Brief Summary

The purpose of the Primary Tube Versus Trabeculectomy (PTVT) Study is to compare the long-term safety and efficacy of nonvalved tube shunt surgery to trabeculectomy with mitomycin C in eyes that have not had previous ocular surgery.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
242

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Apr 2008

Longer than P75 for phase_4

Geographic Reach
3 countries

16 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2008

Completed
22 days until next milestone

First Submitted

Initial submission to the registry

April 23, 2008

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 24, 2008

Completed
12.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2021

Completed
1.6 years until next milestone

Results Posted

Study results publicly available

October 19, 2022

Completed
Last Updated

October 19, 2022

Status Verified

October 1, 2022

Enrollment Period

13 years

First QC Date

April 23, 2008

Results QC Date

August 16, 2022

Last Update Submit

October 18, 2022

Conditions

Keywords

Tube shunt surgeryTrabeculectomy

Outcome Measures

Primary Outcomes (1)

  • Number of Participants With Surgical Failure

    Surgical failure is defined as: 1. Inadequate Intraocular Pressure (IOP) Reduction (IOP \> 21 mmHg or reduced \< 20% below baseline on 2 consecutive follow-up visits after 3 months) 2. Reoperation for glaucoma 3. Persistent hypotony (IOP ≤ 5 mmHg on 2 consecutive visits after 3 months) 4. Loss of light perception vision

    Up to 5 years

Secondary Outcomes (7)

  • Intraocular Pressure

    At baseline, At 1 year, At 18 months, At 2 years, At 3 years, At 4 years, At 5 years

  • Number of Participants With Reported Postoperative Complications

    Up to 5 years

  • Visual Acuity Using a Snellen Chart

    At Baseline, At 5 years

  • Visual Acuity as Measured Using EDTRS Chart

    At baseline, At 5 years

  • Visual Field

    Up to 5 years

  • +2 more secondary outcomes

Study Arms (2)

Tube shunt surgery group

EXPERIMENTAL

Participants in this group will receive a tube shunt surgery (Baerveldt Glaucoma implant).

Procedure: Tube shunt surgery

Trabeculectomy with Mitomycin C

EXPERIMENTAL

Participants in this group will receive a Trabeculectomy surgery with Mitomycin C

Procedure: TrabeculectomyDrug: Mitomycin C

Interventions

The procedure involves implantation of a Baerveldt consisting of a tube that is connected to an end plate. The tube is inserted into the anterior chamber and shunts aqueous humor to the end plate located in the equatorial region of the eye. The aqueous humor is then absorbed by the tissues around the eye.

Also known as: Baerveldt glaucoma implant
Tube shunt surgery group

The procedure involves removal of a small portion of trabecular meshwork and adjacent tissue under a partial thickness scleral flap. Aqueous humor drains into the subconjunctival space producing a filtering bleb. The aqueous humor then diffuse out of the bleb.

Trabeculectomy with Mitomycin C

A fluid retaining sponge soaked in 0.4 mg/ml Mitomycin C will be applied in the region of Trabeculectomy site for about 2 minutes

Trabeculectomy with Mitomycin C

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18-85 years
  • Glaucoma that is inadequately controlled on tolerated medical therapy with Intraocular Pressure (IOP) greater than or equal to 18 mm Hg and less than or equal to 40 mm Hg
  • No previous incisional ocular surgery

You may not qualify if:

  • Unwilling or unable to give consent, unwilling to accept randomization, or unable to return for scheduled protocol visits
  • Pregnant or nursing women
  • No light perception vision
  • Active iris neovascularization or active proliferative retinopathy
  • Iridocorneal endothelial syndrome
  • Epithelial or fibrous ingrowth
  • Chronic or recurrent uveitis
  • Steroid-induced glaucoma
  • Severe posterior blepharitis
  • Unwilling to discontinue contact lens use after surgery
  • Previous cyclodestructive procedure
  • Conjunctival scarring from prior ocular trauma or cicatrizing disease precluding a superior trabeculectomy
  • Functionally significant cataract
  • Need for glaucoma surgery combined with other ocular procedures or anticipated need for additional ocular surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (16)

University of California Davis Medical Center

Sacramento, California, 95817, United States

Location

University of Florida

Gainesville, Florida, 32610, United States

Location

Bascom Palmer Eye Institute

Miami, Florida, 33136, United States

Location

Johns Hopkins

Baltimore, Maryland, 21290, United States

Location

St. Louis University

St Louis, Missouri, 63104, United States

Location

New York Eye and Ear Infirmary

New York, New York, 10003, United States

Location

Cincinnati Eye Institute

Cincinnati, Ohio, 45242, United States

Location

University of Oklahoma

Oklahoma City, Oklahoma, 73104, United States

Location

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location

Glaucoma Associates of Texas

Dallas, Texas, 75231, United States

Location

University of Texas, Houston

Houston, Texas, 77030, United States

Location

University of Virginia

Charlottesville, Virginia, 22908, United States

Location

University of Toronto

Toronto, Canada

Location

Moorfields Eye Hospital

London, United Kingdom

Location

St. Thomas' Hospital

London, United Kingdom

Location

Queen Mary's Sidcup Hospital

Sidcup, United Kingdom

Location

Related Publications (4)

  • Gedde SJ, Chen PP, Heuer DK, Singh K, Wright MM, Feuer WJ, Schiffman JC, Shi W; Primary Tube Versus Trabeculectomy Study Group. The Primary Tube Versus Trabeculectomy Study: Methodology of a Multicenter Randomized Clinical Trial Comparing Tube Shunt Surgery and Trabeculectomy with Mitomycin C. Ophthalmology. 2018 May;125(5):774-781. doi: 10.1016/j.ophtha.2017.10.037. Epub 2017 Dec 18.

    PMID: 29248173BACKGROUND
  • Gedde SJ, Feuer WJ, Lim KS, Barton K, Goyal S, Ahmed IIK, Brandt JD; Primary Tube Versus Trabeculectomy Study Group. Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 3 Years of Follow-up. Ophthalmology. 2020 Mar;127(3):333-345. doi: 10.1016/j.ophtha.2019.10.002. Epub 2019 Oct 9.

  • Gedde SJ, Feuer WJ, Shi W, Lim KS, Barton K, Goyal S, Ahmed IIK, Brandt J; Primary Tube Versus Trabeculectomy Study Group. Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 1 Year of Follow-up. Ophthalmology. 2018 May;125(5):650-663. doi: 10.1016/j.ophtha.2018.02.003. Epub 2018 Feb 21.

  • Gedde SJ, Feuer WJ, Chen PP, Heuer DK, Singh K, Wright MM; Tube Versus Trabeculectomy and Primary Tube Versus Trabeculectomy Study Groups. Comparing Treatment Outcomes from the Tube Versus Trabeculectomy and Primary Tube Versus Trabeculectomy Studies. Ophthalmology. 2021 Feb;128(2):324-326. doi: 10.1016/j.ophtha.2020.06.059. Epub 2020 Jul 2.

MeSH Terms

Conditions

Glaucoma

Interventions

Glaucoma Drainage ImplantsTrabeculectomyMitomycin

Condition Hierarchy (Ancestors)

Ocular HypertensionEye Diseases

Intervention Hierarchy (Ancestors)

Prostheses and ImplantsEquipment and SuppliesFiltering SurgeryOphthalmologic Surgical ProceduresSurgical Procedures, OperativeMitomycinsIndolequinonesQuinonesOrganic ChemicalsAzirinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsIndolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Results Point of Contact

Title
Steven Gedde, MD
Organization
University of Miami

Study Officials

  • Steven J Gedde, MD

    Bascom Palmer Eye Institute

    STUDY CHAIR
  • Dale K Heuer, MD

    Medical College of Wisconsin

    STUDY CHAIR
  • Richard K Parrish, MD

    Bascom Palmer Eye Institute

    STUDY CHAIR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr

Study Record Dates

First Submitted

April 23, 2008

First Posted

April 24, 2008

Study Start

April 1, 2008

Primary Completion

April 1, 2021

Study Completion

April 1, 2021

Last Updated

October 19, 2022

Results First Posted

October 19, 2022

Record last verified: 2022-10

Data Sharing

IPD Sharing
Will not share

Locations